Author:
Mokuolu Olugbenga Ayodeji,Bolarinwa Oladimeji Akeem,Opadiran Oluwatumobi Racheal,Ameen Hafsat Abolore,Dhorda Mehul,Cheah Phaik Yeong,Amaratunga Chanaki,de Haan Freek,Tindana Paulina,Dondorp Arjen M.
Abstract
Abstract
Background
Recent reports of artemisinin partial resistance from Rwanda and Uganda are worrisome and suggest a future policy change to adopt new anti-malarials. This is a case study on the evolution, adoption, and implementation of new anti-malarial treatment policies in Nigeria. The main objective is to provide perspectives to enhance the future uptake of new anti-malarials, with an emphasis on stakeholder engagement strategies.
Methods
This case study is based on an analysis of policy documents and stakeholders’ perspectives drawn from an empirical study conducted in Nigeria, 2019–2020. A mixed methods approach was adopted, including historical accounts, review of programme and policy documents, and 33 qualitative in-depth interviews and 6 focus group discussions.
Results
Based on policy documents reviewed, the adoption of artemisinin-based combination therapy (ACT) in Nigeria was swift due to political will, funding and support from global developmental partners. However, the implementation of ACT was met with resistance from suppliers, distributors, prescribers, and end-users, attributed to market dynamics, costs and inadequate stakeholder engagement. Deployment of ACT in Nigeria witnessed increased developmental partner support, robust data generation, ACT case-management strengthening and evidence on anti-malarial use in severe malaria and antenatal care management. A framework for effective stakeholder engagement for the future adoption of new anti-malarial treatment strategies was proposed. The framework covers the pathway from generating evidence on drug efficacy, safety and uptake; to making treatment accessible and affordable to end-users. It addresses which stakeholders to engage with and the content of engagement strategies with key stakeholders at different levels of the transition process.
Conclusion
Early and staged engagement of stakeholders from global bodies to community level end-users is critical to the successful adoption and uptake of new anti-malarial treatment policies. A framework for these engagements was proposed as a contribution to enhancing the uptake of future anti-malarial strategies.
Funder
UK aid and the UK Government’s Foreign, Commonwealth & Development Office
Wellcome Trust Centre for Mitochondrial Research
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference59 articles.
1. WHO. Global technical strategy for malaria 2016–2030. Geneva: World Health Organization; 2016.
2. Bosman A, Delacollette C, Olumese P, Ridley R, Shretta AR, et al. The use of antimalarial drugs: report of an informal consultation. Geneva: World Health Organization; 2001.
3. Humphreys K, Piot P. Scientific evidence alone is not sufficient basis for health policy. BMJ. 2012;344: e1316.
4. Webster J, Hoyt J, Diarra S, Manda-Taylor L, Okoth G, Achan J, et al. Adoption of evidence-based global policies at the national level: Intermittent preventive treatment for malaria in pregnancy and first trimester treatment in Kenya, Malawi, Mali and the Gambia. Health Policy Plan. 2020;35:1364–75.
5. de Haan F, Moors EHM, Dondorp AM, Boon WPC. Market formation in a global health transition. Environ Innov Soc Transit. 2021;40:40–59.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献